FLORHAM PARK, NJ – NOV 20, 2012 -- Defined Health is pleased to announce the addition of the panel, “Growing a Cancer-Focused Biotech: Learning from Previous and Current Business Models” to the 24th annual Cancer Progress conference. Cancer Progress 2013 will be held on March 5th-6th, 2013 at The Conrad, New York. This unprecedented panel will feature the following biopharma executives and industry veterans:

Cancer Progress has an outstanding reputation as the premier annual oncology conference that affords a unique dialogue among experts in the cancer field. Scientific and clinical opinion leaders and industry executives offer valuable insights and candid assessments of key issues impacting oncology research, development and commercialization. See the full program at: www.CancerProgressbyDH.com

The 2013 program includes the following speakers and panelists, to date:

Founded more than 25 years ago, Defined Health (http://www.definedhealth.com) is a leading biopharmaceutical business development strategy consulting firm whose clients include large and mid-sized pharma, large cap and emerging biotech and specialty pharmaceutical companies. Defined Health's consultants hold advanced degrees in science, medicine and business, and have industry experience in business development, commercial evaluation, finance, licensing, drug discovery and R&D.

Oncology is one of Defined Health’s most active areas of research. “Defined Health is pleased to have the opportunity to build upon Communitech’s great success in building this outstanding conference by bringing to bear our rich knowledge of the cancer space. After attending myself for the past ten years, it is a great honor and very exciting to now be planning the program, with input from the academic and industry advisors who have admirably contributed to the program over the course of its history,” remarks Jeff Bockman, PhD, who heads up Defined Health’s cancer practice.

For more information and to register: www.cancerprogressbydh.com / www.definedhealth.com